RSS
X-linked hypophosphatemia (XLH)
NICE recommends Crysvita for treatment of rare bone disorder in young patients
The National Institute for Health and Care Excellence (NICE) has given a positive recommendation for Crysvita (burosumab) to be used in the treatment of X-linked hypophosphataemia (XLH) in children and young people with growing bones. Read more
EC grants conditional marketing authorisation for Crysvita
The European Commission (EC) has revealed its decision to grant conditional marketing authorisation to Kyowa Kirin for Crysvita (burosumab) to treat X-linked hypophosphatemia (XLH) with radiographic evidence of bone disease in children & adolescents Read more
